CA2718113A1 - Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway - Google Patents

Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway Download PDF

Info

Publication number
CA2718113A1
CA2718113A1 CA2718113A CA2718113A CA2718113A1 CA 2718113 A1 CA2718113 A1 CA 2718113A1 CA 2718113 A CA2718113 A CA 2718113A CA 2718113 A CA2718113 A CA 2718113A CA 2718113 A1 CA2718113 A1 CA 2718113A1
Authority
CA
Canada
Prior art keywords
patient
treatment
patients
spectrum
mass spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718113A
Other languages
English (en)
French (fr)
Inventor
Heinrich Roeder
Maxim Tsypin
Julia Grigorieva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biodesix Inc
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of CA2718113A1 publication Critical patent/CA2718113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Computing Systems (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Software Systems (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
CA2718113A 2009-01-20 2009-11-20 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway Abandoned CA2718113A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/321,393 2009-01-20
US12/321,393 US7867775B2 (en) 2006-03-31 2009-01-20 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
PCT/US2009/006269 WO2010085235A1 (en) 2009-01-20 2009-11-20 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Publications (1)

Publication Number Publication Date
CA2718113A1 true CA2718113A1 (en) 2010-07-29

Family

ID=41559566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718113A Abandoned CA2718113A1 (en) 2009-01-20 2009-11-20 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Country Status (11)

Country Link
US (1) US7867775B2 (enExample)
EP (1) EP2247954B1 (enExample)
JP (1) JP5025802B2 (enExample)
KR (1) KR101131309B1 (enExample)
AT (1) ATE516503T1 (enExample)
AU (1) AU2009338174B2 (enExample)
CA (1) CA2718113A1 (enExample)
ES (1) ES2368784T3 (enExample)
IL (1) IL211943A (enExample)
TW (1) TWI368737B (enExample)
WO (1) WO2010085235A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
KR101556726B1 (ko) * 2010-02-24 2015-10-02 바이오디식스, 인크. 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US8718996B2 (en) 2012-07-05 2014-05-06 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
CN112710723B (zh) 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
WO2018129301A1 (en) 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
EP3665199A4 (en) 2017-08-07 2021-08-11 Genecentric Therapeutics, Inc. METHOD OF SUBTYPING PLATE EPITHELIAL CARCINOMA OF THE HEAD AND NECK
US20210074431A1 (en) * 2017-08-30 2021-03-11 Genecentric Therapeutics, Inc. Gene expression subtype analysis of head and neck squamous cell carcinoma for treatment management
EP3773691A4 (en) 2018-03-29 2022-06-15 Biodesix, Inc. DEVICE AND METHOD FOR IDENTIFICATION OF PRIMARY IMMUNORESISTANCE IN CANCER PATIENTS
WO2022084993A1 (en) * 2020-10-19 2022-04-28 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332639D1 (de) 2002-08-06 2010-07-01 Univ Johns Hopkins Verwendung von biomarkern zum nachweis von eierstockkrebs
JP2007506442A (ja) 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
WO2005098445A2 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
EP2439284B1 (en) * 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

Also Published As

Publication number Publication date
IL211943A0 (en) 2011-06-30
EP2247954A1 (en) 2010-11-10
JP5025802B2 (ja) 2012-09-12
TW201028688A (en) 2010-08-01
US7867775B2 (en) 2011-01-11
ES2368784T3 (es) 2011-11-22
TWI368737B (en) 2012-07-21
US20090171872A1 (en) 2009-07-02
AU2009338174B2 (en) 2012-02-02
IL211943A (en) 2014-01-30
KR101131309B1 (ko) 2012-04-02
KR20110047171A (ko) 2011-05-06
AU2009338174A1 (en) 2010-07-29
ATE516503T1 (de) 2011-07-15
WO2010085235A1 (en) 2010-07-29
EP2247954B1 (en) 2011-07-13
JP2011513728A (ja) 2011-04-28
HK1148073A1 (en) 2011-08-26

Similar Documents

Publication Publication Date Title
EP2247954B1 (en) Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway
US7858389B2 (en) Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
US7858390B2 (en) Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US8718996B2 (en) Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
TW201237409A (en) Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
HK1148073B (en) Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway
HK1156696B (en) Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20170215